IQVIA Holdings Inc (IQV) stock analysis
IQVIA Holdings Inc (IQV) clears 4 of this site's 8 mechanical value filters, 4 of 8 Buffett-style checks and 2 of 5 Lynch-style checks. At $278.32 it trades 21.7% above this site's neutral DCF value (a margin of safety of -21.7%). Its earnings quality rates Strong and it returns +2.2% to shareholders net of dilution. Figures are as of October 23, 2026, from SEC filings and market data refreshed weekly; this is educational analysis, not investment advice.
Data as of October 23, 2026. Refreshed weekly from SEC filings and market data.
What does IQVIA do?
IQVIA runs clinical trials for drugmakers on an outsourced basis and sells health-data analytics. It is one of the largest research organizations (CROs) serving the pharmaceutical industry.
What stands out about IQVIA?
- The share price implies 12.9% yearly growth. At $278.32, IQV's free cash flow of $13.39 per share would have to grow 12.9% a year, fading to 2.5% by year 10, for this site's DCF (10% discount rate) to match the price. This site's baseline starts at 8%, so the price asks for more growth than the baseline. Change the assumptions.
- Misses 2 of the 8 value filters. It fails Trailing P/E < 25 (33.01) and PEG Ratio < 1.5 (2.05); the other 4 pass and 2 were not evaluated. See every filter.
- The margin of safety is falling. It went from -16% on Oct 7 to -22% on Oct 23 across 5 weekly readings. See the trend.
- Strongest against peers: free-cash-flow yield. At 4.8% (peer median 2.5%) it ranks 1st of 11 among life sciences tools & services stocks this site tracks. See the ranking.
- Weakest against peers: debt / equity. At 2.59 (peer median 0.54) it ranks 10th of 11 among life sciences tools & services stocks this site tracks. See the ranking.
How has IQVIA's share price moved?
The interactive price chart needs JavaScript.
Is IQVIA undervalued? The value diligence check
Every value-investing signal this site computes for this stock, gathered in one place: the same real numbers from the tools below, not a new score.
- Margin of safety (DCF) -21.7%
- P/E vs. its own history 33.0x · near the cheap end Real range: 26.3x–57.0x over 5 years (net income per diluted share from each fiscal year's 10-K, paired with the real closing price at that fiscal year-end).
- Wall St. analyst rating Buy · 4.19/5 27 analysts this month: 9 strong buy, 14 buy, 4 hold, 0 sell, 0 strong sell (Finnhub). Up from 4.14 last month.
- Altman Z″-Score (bankruptcy risk) 1.14 · Grey zone
- Earnings quality (is the profit real?) Strong · all 5 checks clean Beneish M-score −2.62 · accruals −4.6% of assets · 184% of profit arrived as cash · stock comp 1.5% of revenue · share count −3.5% a year. From the latest 10-K (year to Dec 2025) - see the Earnings Quality Screener for how each check is scored.
- Shareholder yield (cash back to owners) +2.2% net Latest fiscal year (2025): dividends 0.0% + buybacks 2.7% − stock comp 0.5%, as a share of today's market cap. Over 14 years its split-adjusted share count rose 47%. See Shareholder Yield Leaders.
- Capital needed to grow (See's test) $0.72 per $1 of new profit · See's-like · but only 11% return on capital Operating profit $661M → $2.1B, capital needed $18B → $19B, 2016–2025 (3-year averages); return on capital now 11% before tax. Buffett's See's Candies needed $0.42 per $1 of new profit, FlightSafety $3.20, a typical grower about $5. See Capital-Light Compounders.
- PEG (growth at a reasonable price) 2.05 · Well above fair P/E 33.0× ÷ 16.1% a year of growth behind it. 229th lowest of 447 stocks with a usable PEG. Lynch's fair value is a PEG of 1; a very high PEG usually means almost no growth, a very low one a profit spike. See PEG Ratio Ranking.
- Compounder lenses (4) 2 of 4 · misses capital-light, price Capital-light growth: not cleared (only 11% return on capital); Profit is real: cleared; Cash to owners: cleared; Fair price (PEG): not cleared (PEG 2.05, over 1.5). See Compounders at a Fair Price, which also lets you move the PEG bar.
- Value trap check Clear
- Munger's Inversion Check 2 flags
- Standing vs. sector peers 4 of 6 measures above the median Compared with the 10 other life sciences tools & services stocks this site tracks: 3 in the top third, 2 in the bottom third.
How does IQVIA compare with its peers?
4 of 6 measures sit above the median of the 10 other life sciences tools & services stocks tracked here, 3 in the top third and 2 in the bottom third.
- P/E ratiolower is cheaper · peer median 43.4× 33.0× ✓1st of 10
- Free-cash-flow yieldhigher is cheaper · peer median 2.5% 4.8% ✓1st of 11
- Return on equityhigher is better · peer median 13% 22% ✓3rd of 11
- Net marginhigher is better · peer median 15.0% 8.1% ✕9th of 11
- Revenue growthhigher is better, year on year · peer median 6.9% 8.2% –5th of 11
- Debt / equitylower is safer · peer median 0.54 2.59 ✕10th of 11
Peers are the stocks this site tracks in the same sector group, not every listed competitor. The bar runs from the weakest peer (left) to the strongest (right); the tick is the middle. Measures that don't apply to a sector (cash-flow yield for banks, debt for financials) are left out.
What would Buffett & Lynch say?
Buffett's checklist is built around durable, profitable businesses bought at sensible prices, and IQV doesn't clear enough of it yet. In its favor: IQV is currently earning a strong return on shareholders' equity, and has kept that profitability up over five years, not just this year, has grown earnings per share at a solid clip over five years, and trades at a reasonable multiple of owner earnings, his own term for the real cash a business could pay out. Where it comes up short: IQV carries more debt relative to equity than he typically tolerates, runs thinner pretax margins than he'd like to see, doesn't cover its interest expense as comfortably as he'd want, and is trading above what a conservative discounted-cash-flow estimate says it's worth right now.
- ROE (TTM) > 11% ✓
- ROE (5yr avg) > 11% ✓
- Debt/Equity < 0.5 ✕
- Pretax margin > 15% ✕
- EPS growth (5yr) > 7% ✓
- Interest coverage > 5x ✕
- Trading below intrinsic value (DCF) ✕
- Price vs. owner earnings < 25x ✓
- Bonus: returning capital via buybacks FY2025
Lynch looked for growth stories that weren't overpriced for that growth, and IQV falls short of his bar. In its favor: IQV is growing earnings at the steady 10-20% pace of a proper Stalwart, and is backing its growth up with real free cash flow. Where it comes up short: IQV fails his signature PEG test, he'd call this pricey for the growth on offer, carries more debt than he liked to see, even allowing for the extra room a large, stable business gets, and is asking investors to pay a steep multiple for that growth.
- PEG < 1 ✕
- EPS growth 10%-20% ✓
- Debt/Equity < 0.6 ✕
- P/E < 27 ✕
- Price/FCF < 30 ✓
Quantitative approximations of each investor's documented approach, not endorsed by either investor or their estates - commentary, not this site's actual ranking criteria. Buffett never published a numeric checklist: only 2 of his 8 checks here trace to his own documented concepts ("owner earnings," from his 1986 shareholder letter, and "price is what you pay, value is what you get," his case against fixed P/E/P/B ceilings) - the other 6 (ROE, debt, margins, growth, interest coverage) use commonly-cited thresholds that are not numbers he himself published. The 8 hard filters below (plus the Munger check and Graham margin of safety) are this site's real, mechanical screen and are computed completely independently of the checklists above.
Berkshire Hathaway's own filing
Which of the 8 value filters does IQVIA pass?
- Market Cap > $25B $45.4B
- Trailing P/E < 25 33.01
- PEG Ratio < 1.5 2.05
- Price/Book < 8 7.36
- Price/Sales < 7 2.67
- EPS Growth YoY > -5% -0.4%
- vs 50-day MA (±12%) Not evaluated †
- vs 200-day MA (±12%) Not evaluated †
What is IQVIA's margin of safety?
-16% on 2026-10-07 → -22% on 2026-10-23 (5 weekly readings).
Where is IQVIA in its 52-week range?
What is the short interest in IQVIA?
3,216,119 shares short as of 2026-09-30 (FINRA settlement date). Reported twice a month, so this only changes roughly every two weeks, not daily.
What could go wrong with IQVIA? Munger's inversion check
"Invert, always invert." Instead of reasons to buy, these are reasons to hesitate, not a verdict, and not everything worth knowing about a business.
- Margin of safety, even in the bull case +28%
- Short interest under 5% of float 2.0%
- Passes most of the 6 fundamental filters 4/6 passed
- Price run-up backed by value, not just momentum +77% off 52wk low
- Debt/equity stable since 2016 0.82 → 2.37
Doesn't cover circle of competence, management quality, or accounting concerns: those need judgment, not data.
How much have IQVIA shareholders gained per year?
Earnings growth per share plus dividend.
An earnings-based proxy, not a stock-price total return - it doesn't capture multiple expansion/contraction or reinvested dividends. EPS from IQV's own 10-K filings; dividend yield is the current trailing yield on today's price, from the same weekly fetch as the rest of this site.
What do IQVIA's 10-year financials show?
From IQV's own 10-K filings (SEC EDGAR): up to the last 10 fiscal years. Press any year's bars for the exact figures.
Frequently asked questions about IQVIA
What kind of company is IQVIA?
IQVIA runs clinical trials for drugmakers on an outsourced basis and sells health-data analytics. It is one of the largest research organizations (CROs) serving the pharmaceutical industry. This site groups it with Life Sciences Tools & Services stocks.
Is IQVIA trading above or below its DCF value?
At $278.32, IQV trades 21.7% above this site's neutral DCF value of $228.69 per share, a margin of safety of −21.7%. That DCF projects free cash flow for 10 years, with growth starting at 8% and fading to 2.5%, discounted at 10%; it is one set of assumptions, not a forecast. Test your own in the Intrinsic Value Calculator.
How many of this site's 8 value filters does IQVIA pass?
IQV passes 4 of 8. It passes Market Cap > $25B ($45.4B), Price/Book < 8 (7.36), Price/Sales < 7 (2.67) and EPS Growth YoY > -5% (-0.4%). It misses Trailing P/E < 25 (33.01) and PEG Ratio < 1.5 (2.05). vs 50-day MA (±12%) and vs 200-day MA (±12%) were not evaluated, because the moving-average checks only run on stocks that clear the fundamentals first. The 8-filter list shows every stock that passes all of them.
Where is IQVIA trading compared with its 52-week range?
At $278.32, IQV is at its 52-week high of $276.67, 76.6% above its 52-week low of $156.66.
How risky is IQVIA's balance sheet?
IQV's Altman Z″-Score is 1.14, which falls in the grey zone. Altman's own thresholds are above 2.6 for the safe zone, 1.1 to 2.6 for the grey zone and below 1.1 for the distress zone; the score blends working capital, retained earnings, operating profit and equity against liabilities. Its debt-to-equity ratio is 2.59. See the Altman Z″-Score list.
When does IQVIA report earnings next?
IQVIA's next earnings report is expected on October 27, 2026 before the market opens, with analysts expecting earnings of $3.31 per share. Dates come from the Finnhub earnings calendar and can move. In its last 4 quarters it beat the estimate 2 times, by an average of +1.1%.
Where do these numbers come from?
- Financial statements: IQVIA's 10-K annual report for the year ended Dec 31, 2025, filed Feb 17, 2026 (filing index). Every earlier year in the 10-year financials comes from the company's older 10-K filings, all listed on SEC EDGAR.
- Prices and market data: quotes, P/E and analyst ratings from Finnhub; daily price history and the 52-week range from Twelve Data, both refreshed weekly. Short interest comes from FINRA, reported twice a month.
- How to check a figure: click any number in the card above to see its exact source, and read the Editorial Standards for every rule behind the checks.
About this IQVIA Holdings Inc analysis
This page shows every value-investing check the site runs on IQVIA Holdings Inc (IQV) in one place: the 8 mechanical filters, the Buffett and Lynch checklists, a margin of safety from a disclosed DCF, earnings quality, shareholder yield and how it ranks against its sector peers. The numbers come from SEC filings and public market data, refreshed weekly, and the same rules apply to every stock on the stock list. See Editorial Standards for the sources and the rules, or run your own filters in the stock screener.